The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.20
Ask: 3.30
Change: 0.00 (0.00%)
Spread: 0.10 (3.125%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Amigo heads to vote; UniVision court date pushed back

Tue, 15th Mar 2022 17:18

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Amigo Holdings PLC- guarantor loans provider - Says high court grants order that schemes of arrangement can proceed to a creditor vote. "The road ahead is not easy, but we are on the right track and today's court decision is another step forward," says Chief Executive Gary Jennison. Creditors' meeting to be held in May and, if they vote for the scheme, the court sanction hearing is expected to be held later that month. Scheme is being proposed to settle claims following probes from UK regulators into mis-sold loans and the way that Amigo dealt with customer complaints. Jennison says "significant hurdles remain". Adds: "We are pleased that the court has agreed that the schemes can proceed to a creditor vote. The financial offer has been significantly improved and we will be doing everything we can to encourage creditor participation."

----------

Digital 9 Infrastructure PLC - London-based digital infrastructure investor - Signs new GBP300 million revolving credit facility with an international syndicate of four banks including the Royal Bank of Scotland International Ltd, DNB Ltd, Royal Bank of Canada and Banco Santander. "Triple Point Investment Management LLP, the group's investment manager, continues to identify attractive investment opportunities for the company's portfolio. The new RCF will provide the group with additional committed capital, to help finance the acquisition of further investments from its near-term pipeline. The investment manager remains focused on converting its pipeline of about GBP2 billion of potential assets," company says.

----------

Aptitude Software Group PLC - London-based finance transformation and automation software - Decides to further increase investment in product strategy in 2022 and 2023, though warns this is expected to "dampen short term profitability". "The board believes this accelerated strategic investment will create longer term sustainable value for the group and our shareholders," it says. Expects improving margins from 2024 and beyond. This comes alongside annual results for 2021, in which total revenue rises 3% to GBP59.3 million but pretax profit falls to GBP6.2 million from GBP8.1 million in 2020.

----------

Mobile Streams PLC - mobile content provider - Raises GBP1.2 million in placing priced at 0.30p per share. Funds to support company's growth and to create a new joint venture partnership with Gfinity PLC for Mobilegaming.com. "The company is working to agree the terms of the joint venture and expects to announce the conclusion of the agreement shortly," it says. Gfinity shares rise 6.2%.

----------

Smart Metering Systems PLC - Glasgow-based provider of end-to-end services in utility connections, smart metering and energy management - Pretax profit in 2021 slumps to GBP8.3 million from GBP195.0 million in 2020, which was attributed to a hefty gain from its I&C meter portfolio disposal the year prior. Revenue improves to GBP108.5 million from GBP103.0 million. Annual dividend upped to 27.5 pence from 25.0p. Chief Executive Tim Mortlock says: "Our contracted smart meter order pipeline remains solid and now more favourably weighted to larger, well-financed independent energy suppliers, and supported by the extension to our exclusivity agreement with Shell Energy Retail. We expect our installation rate to progressively increase throughout the coming year."

----------

UniVision Engineering Ltd - Hong Kong-based firm which installs closed circuit television surveillance systems - Court hearing for winding up petition adjourned until April 19, 2022. Hearing regards GBP565,280 alleged debt owed by company to sub-contractor T&P Solutions Ltd, formerly known as T&P Construction Co. Previously says: "The company intends to defend and oppose the petition. The company has separately been advised that it has a cross claim against T&P, inter alia, for breach of contract and non-performance and it intends to claim damages for the same."

----------

ValiRx PLC - cancer and women's health treatment developer - Says it is assessing options to acquire capabilities and infrastructure to create a "more efficient and effective" translational drug development service. Says revenue generated from providing pre-clinical development services would enable continued investment in advanced testing and analysis technology and support the progression of ValiRx in-house pipeline projects.

----------

Tlou Energy Ltd - power company focused on sub-Saharan Africa - Says contract for the construction of the transmission line to connect the Lesedi power project to Botswana's electricity grid has been signed. Botswana-based Zismo Engineering Pty Ltd has been engaged to construct the line, and expects to mobilise plant and equipment on site in the coming weeks.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
20 Jun 2019 09:54

ValiRx secures 'substantial amendment' to VAL201 clinical trials

(Sharecast News) - Clinical stage biotechnology company ValiRx updated the market on 'VAL201' on Thursday, confirming that, based on clinical results, a "substantial amendment" to the clinical trial protocol had received regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the research ethics committee.

Read more
13 Jun 2019 11:07

ValiRx Subscription Raises GBP300,000 For Drug Trial And Development (ALLISS)

(Alliance News) - ValiRx PLC on Thursday said it raised GBP300,000 via subscription for working capital and to progress the clinical trial of its VALL201 cancer drug.Shares in ValiRx a 31%

Read more
10 Jun 2019 09:50

ValiRx In Discussions With Investor To End Subscription Agreement (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Monday confirmed it is in advanced discussions with European High Growth Opportunities SF to terminate a subscription agreement.Shares in the clinical

Read more
5 Jun 2019 10:54

ValiRx Convertible Bond Talks In Advanced Stage; Plans Open Offer (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Wednesday said it is in advanced discussions with European High Growth Opportunities SF to enter a new convertible bond facility and is planning an open in a

Read more
31 May 2019 12:04

ValiRx Extends Talks With Investor Over New Convertible Bond (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Friday said it has extended the deadline to enter into a new convertible bond with European High Growth Opportunities SF to July 1.The cancer life was

Read more
29 May 2019 10:41

ValiRx Annual Loss Widens On Higher Costs And Fair Value Losses

LONDON (Alliance News) - ValiRx PLC on Wednesday reported a widened annual loss due to higher costs and losses on the fair value of financial assets.For 2018 the life sciences company, on a

Read more
29 May 2019 10:19

ValiRx losses widen as it continues to progress drug development

(Sharecast News) - Life science company ValiRx reported a loss before income tax of £4.83m in its final results on Wednesday, widening from the £3.55m loss it posted a year earlier.

Read more
2 May 2019 15:21

ValiRx Partners With Alpha Blue Ocean And Buys IP Assets Of FIT Bio

LONDON (Alliance News) - ValiRx PLC on Thursday said it has agreed to acquire the IP assets of FIT Bio for EUR5,000 and establish a genetic therapeutic and diagnostic-based joint venture with Blue

Read more
2 May 2019 09:51

ValiRx acquires IP of failed firm FIT Biotech, forms joint venture

(Sharecast News) - Clinical stage biotechnology company ValiRx announced the acquisition of the global granted patents and intellectual property assets of FIT Biotech for a nominal sum on Thursday.

Read more
26 Apr 2019 14:54

ValiRx To Raise GBP1 Million Under Deal With European High Growth (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Friday said it has entered into a GBP1.3 million subscription agreement with European High Growth Opportunities SF.The stock was trading 17% lower on

Read more
26 Mar 2019 10:22

ValiRx Notes ValiSeek Co-Financing Deals For VAL401 Cancer Drug

LONDON (Alliance News) - Biotechnology firm ValiRx PLC on Tuesday said ValiSeek has secured letters of intent from two companies to co-finance the development of cancer drug VAL401.Shares a

Read more
21 Mar 2019 09:53

ValiRx Notes Encouraging Performance Of VAL201 In Cancer Trial

LONDON (Alliance News) - ValiRx PLC on Thursday said an interim inspection of its VAL201 early phase cancer trial shows the drug is performing as predicted.Shares in ValiRx were up 13% at a

Read more
21 Feb 2019 12:46

ValiRx Raises GBP500,000 Through Placing To Advance Clinical Trials (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Thursday raised GBP500,000 through a share placing to expand its clinical trial of VAL201, as well as the VAL301 and VAL101 programmes.ValiRx issued a

Read more
31 Jan 2019 13:37

ValiRx Secures Patent For VAL301 Compound In Russia And China

LONDON (Alliance News) - ValiRx PLC on Thursday said it has been granted a patent allowance for its therapeutic compound VAL301 in both Russia and China.The clinical stage biotechnology has

Read more
31 Jan 2019 10:08

ValiRx allowed patents for VAL401 in Russia and China

(Sharecast News) - Clinical-stage biotechnology company ValiRx announced on Thursday that the patent offices of Russia and China had both granted a patent allowance for its pre-clinical therapeutic compound, VAL301, subject to payment of the relevant fees.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.